Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Philippines FDA/Almic

Approved

STANDARD

Almic

Lloyd Laboratories, Inc.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 86c05af11af5fc58
Company: Lloyd Laboratories, Inc.
Type: Standard

Approval Details

Approval Id: 86c05af11af5fc58
Drug Approval Philippines Name: Almic
Product Name: Almic
Registration Number: DR-XY26113
Brand Name: Almic
Generic Name: Mefenamic Acid
Dosage Form: Oral Suspension
Dosage Strength: 50 mg/5 mL
Manufacturer: Lloyd Laboratories, Inc.
Trader: Vitalink Health Products Inc.
Issuance Date: 29 November 2024
Expiry Date: 10 April 2030
Pharmacologic Category: Non-Steroidal Anti-Inflammatory Drug (NSAID)
Classification: Over-the-Counter (OTC)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

86c05af11af5fc58

Type

Standard

Back to Philippines FDA Approvals

Almic - Philippines FDA Drug Approval Details